EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 641 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence... March 11, 2026 6 highlights from our Black in Cancer conference October 31, 2022 Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... September 11, 2024 Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Load more HOT NEWS Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... Coming Soon: Medicare Drug Price Negotiations Our nurses answer your frequently asked questions about cancer The new home for your research tools
